Table I.
Clinical characteristics and prevalence of risk factors in the study population.
| Variable | CVT patients (n, %) | Controls (n, %) | OR (95% CI) | P^ |
|---|---|---|---|---|
| Gender (F/M) | 41/15 | 134/50 | NS | |
| Age (mean±SD) | 34.98±11.02 | 35.05±11.33 | NS | |
| FII G201210A | 16/55 (29.1%) | 10/183 (5.5%) | 7.09 (2.99–16.82) | <0.0001 |
| FV Leiden | 3/56 (5.4) | 15/183 (8.2%) | 0.6 (0.17–2.274) | NS |
| Antiphospholipid antibodies* | 2/47 (4.3%) | 5/113 (4.4%) | NS | |
| Infectious diseases | 7/55 (12.7%) | 2/183 (1.1%) | 13.19 (2.65–65.59) | <0.001 |
| Cancer and haematological disorders | 7/54 (13%) | 4/183 (2.2%) | 6.66 (1.87–23.72) | 0.003 |
| Oral contraceptive users | 22/41 (53.7%) | 21/132 (15.9%) | 6.12 (2.83–13.23) | <0.0001 |
| Autoimmune diseases | 5/55 (9.1%) | 7/182 (3.8%) | 2.5 (0.76–8.21) | NS |
| Arterial hypertension | 9/56 (16.1%) | 27/182 (14.8%) | 1.09 (0.40–2.50) | NS |
| Hypercholesterolaemia | 23/49 (46.9%) | 46/159 (28.9%) | 2.17 (1.12–4.19) | 0.024 |
| Hyperhomocysteinaemia | 15/44 (34.1%) | 44/148 (29.7%) | 1.22 (0.59–2.50) | NS |
| Obesity (BMI ≥30) | 19/40 (47.5%) | 56/144 (38.9%) | 1.42 (0.70–2.87) | NS |
| Cigarette smoking | 26/55 (47.3%) | 67/183 (36.6%) | 1.52 (0.80–2.80) | NS |
Legend
BMI: body mass index; CI: confidence interval; CVT: cerebral vein thrombosis; FII: prothrombin; FV: factor V; NS: not significant; OR: odds ratio.
^
univariate analysis; at multivariate logistic regression all significant variables were confirmed, with the exception of hypercholesterolaemia.
*
including lupus anticoagulant and/or anticardiolipin antibodies.